Evaxion Biotech AS Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
EVAX Stock | USD 1.45 0.09 5.84% |
Slightly above 52% of Evaxion Biotech's investor base is interested to short. The analysis of the overall investor sentiment regarding Evaxion Biotech AS suggests that many traders are impartial. Evaxion Biotech's investing sentiment can be driven by a variety of factors including economic data, Evaxion Biotech's earnings reports, geopolitical events, and overall market trends.
Evaxion |
Evaxion Biotech AS Reports Earnings Results for the Full Year Ended December 31, 2023 Marketscreener.com
Read at news.google.com
Evaxion Biotech Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Evaxion Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Evaxion Biotech Fundamental Analysis
We analyze Evaxion Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evaxion Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evaxion Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Evaxion Biotech is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Evaxion Biotech AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Evaxion Biotech stock to make a market-neutral strategy. Peer analysis of Evaxion Biotech could also be used in its relative valuation, which is a method of valuing Evaxion Biotech by comparing valuation metrics with similar companies.
Peers
Evaxion Biotech Related Equities
QNRX | Quoin Pharmaceuticals | 28.12 | ||||
BDRX | Biodexa Pharmaceticals | 7.86 | ||||
RVPH | Reviva Pharmaceuticals | 1.67 | ||||
ALLR | Allarity Therapeutics | 1.85 | ||||
PHIO | Phio Pharmaceuticals | 2.05 | ||||
CGEM | Cullinan Oncology | 2.81 | ||||
ZVSA | ZyVersa Therapeutics | 2.91 | ||||
GLUE | Monte Rosa | 3.52 | ||||
RNAZ | Transcode Therapeutics | 3.57 | ||||
ZURA | Zura Bio | 3.57 | ||||
UNCY | Unicycive Therapeutics | 4.05 | ||||
VRAX | Virax Biolabs | 4.62 | ||||
LYEL | Lyell Immunopharma | 6.00 | ||||
RVMD | Revolution Medicines | 6.89 | ||||
REVB | Revelation Biosciences | 46.32 |
Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.